“…Because of this role, α-glucosidase has been proposed as a potential therapeutic target for the treatment of type-2 diabetes in people. [14,15] In the literature, it is observed that many newly synthesized organic compounds including isatin mannich bases, [16] tetrahydropyrimidine-5-carboxylates, [17] diaryl ethers, [18] 4,5-disubstituted-2-thioxo-1,2,3,4-tetrahydropyrimidines, [19] bromophenols, [20] cyclic thioureas, [21] sulfamides derived from βbenzylphenethylamines, [22] new amides and thiazolidineones synthesized on an acetophenone base, [23] aminomethyl and alkoxymethyl derivatives, [24] 2-hydroxyethyl substituted NHC precursors, [25] phloroglucinol derivatives, [26] novel N,N'-biscyanomethylamine and alkoxymethylamine derivatives, [27] Meta-cyanobenzyl substituted benzimidazoles, [28] novel amides of 1,1-bis-(carboxymethylthio)-1-arylethanes, [29] novel trischalcones, [30] imidazole derivatives, bis-sulfone derivatives, [31] novel benzo[b]xanthene derivatives, [32] nitrogen, phosphorus, selenium and sulfur-containing heterocyclic compounds, [33] Schiff bases containing phenol ring, [34] and piperazine derivatives [35] effectively inhibit AChE and BChE enzymes. All of these newly synthesized molecules, which inhibit both cholinergic enzymes, contain many functional groups that are important for biological activity.…”